Crestor™ Helps More African Americans with Hypercholesterolaemia Achieve Cholesterol Goals

Results from the ARIES study presented today at the American Heart Association's Annual Scientific Sessions demonstrate
that CRESTOR 10 and 20mg reduce LDL-cholesterol (LDL-C or "bad" cholesterol) significantly more and raise HDL-cholesterol
(HDL-C or "good" cholesterol) more than atorvastatin 10 and 20mg in African Americans with hypercholesterolaemia, and enable
more patients to achieve their US NCEP ATP III guideline LDL-C goals.


Cardiovascular disease (CVD) is estimated to account for approximately a third of all deaths globally and is the leading
cause of mortality in the US. African Americans have higher CVD and stroke death rates than Caucasians, and approximately 40
percent of African American men and women age 20 and older have CVD.


"As an African American physician who treats a large number of African-American patients, the ARIES trial represents an
opportunity to demonstrate the efficacy and safety of statins in this high-risk, undertreated and underserved population,"
said Dr. Keith C. Ferdinand, clinical cardiologist and medical director of Heartbeats Life Center and the lead investigator
for ARIES. "ARIES is the first trial to demonstrate superiority in lowering LDL-cholesterol (bad cholesterol) in this
population using rosuvastatin (CRESTOR) compared to atorvastatin, comparing equal doses of each."


Results from ARIES, involving 774 African American adults with hypercholesterolaemia, show that at six weeks:


-- CRESTOR 10mg reduces LDL-C significantly more than atorvastatin 10mg (-37 percent versus -32 percent, respectively;
p